A post hoc analysis on hospitalization risk in Asian patients with schizophrenia switching to once-monthly paliperidone palmitate from oral antipsychotics

Expert Opinion on Pharmacotherapy
Nan LiWilson Tan

Abstract

Background: In this post hoc analysis in patients recently diagnosed (≤5 years) with schizophrenia, the effect on hospitalization risk after switching from oral antipsychotic to once-monthly paliperidone palmitate (PP1M) was evaluated. Research design and methods: Change in hospitalization risk following PP1M initiation among patients switching from oral antipsychotics was assessed using prescription sequence symmetry analysis. Hospitalization risk was expressed as an adjusted sequence ratio (ASR) of the number of patients hospitalized prior to PP1M initiation/post PP1M initiation. Cumulative distribution of the time to hospitalization was estimated by the Kaplan-Meier method and symmetry of distribution was assessed using log-rank test. Hazard ratio and 95% CI were calculated using the Cox proportional hazard model. Results: The number of patients hospitalized after switching to PP1M: no change, 203/300 (67.7%); increase, 18/300 (6.0%); and decrease, 79/300 (26.3%). Following PP1M initiation, ASR (95% CI) was 3.56 (2.67, 5.33) suggesting asymmetry and a significant decline in hospitalization risk. Asymmetry in distribution of hospitalization events with significant (p ≤ 0.001) delay in time to hospitalization was also observed...Continue Reading

References

Jun 1, 1994·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T R Barnes, D A Curson
Apr 30, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Dawn I VelliganAlexander L Miller
Sep 10, 2003·Journal of the American Academy of Dermatology·Kimberly HersomJohn S Strauss
Mar 1, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neeltje E M van HarenRené S Kahn
May 29, 2009·Cost Effectiveness and Resource Allocation : C/E·Douglas E FariesHaya Ascher-Svanum
Mar 3, 2011·The American Journal of Psychiatry·Jari TiihonenPasi Korhonen
Dec 20, 2011·Clinical Therapeutics·Christoph U CorrellJohn M Kane
May 30, 2014·Schizophrenia Bulletin·Peter F BuckleyUNKNOWN PROACTIVE Study
Nov 2, 2014·Therapeutic Advances in Psychopharmacology·Sofia BrissosVicent Balanzá-Martinez
Mar 21, 2015·Neuropsychiatric Disease and Treatment·Fan ZhangSteve Ascher
Oct 4, 2015·Schizophrenia Research·Andreas SchreinerLudger Hargarter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here